A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Status: Recruiting
Location: See all (46) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Have a documented diagnosis of HAE (Type I or II)
• Completed Study ADX-324-301
• Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)
Locations
United States
Arkansas
ADARx Clinical Site
NOT_YET_RECRUITING
Little Rock
Arizona
ADARx Clinical Site
NOT_YET_RECRUITING
Litchfield Park
California
ADARx Clinical Site
NOT_YET_RECRUITING
San Diego
ADARx Clinical Site
NOT_YET_RECRUITING
Walnut Creek
Florida
ADARx Clinical Site
NOT_YET_RECRUITING
Orlando
Maryland
ADARx Clinical Site
NOT_YET_RECRUITING
Chevy Chase
ADARx Clinical Site
NOT_YET_RECRUITING
Wheaton
Michigan
ADARx Clinical Site
NOT_YET_RECRUITING
Detroit
Missouri
ADARx Clinical Site
NOT_YET_RECRUITING
St Louis
Nevada
ADARx Clinical Site
RECRUITING
Las Vegas
New York
ADARx Clinical Site
NOT_YET_RECRUITING
New York
Ohio
ADARx Clinical Site
NOT_YET_RECRUITING
Cincinnati
ADARx Clinical Site
NOT_YET_RECRUITING
Columbus
ADARx Clinical Site
NOT_YET_RECRUITING
Toledo
Pennsylvania
ADARx Clinical Site
NOT_YET_RECRUITING
Hershey
Other Locations
Argentina
ADARx Clinical Site
NOT_YET_RECRUITING
Buenos Aires
ADARx Clinical Site
NOT_YET_RECRUITING
Capital Federal
Australia
ADARx Clinical Site
NOT_YET_RECRUITING
Adelaide
Austria
ADARx Clinical Site
NOT_YET_RECRUITING
Vienna
Belgium
ADARx Clinical Site
NOT_YET_RECRUITING
Edegem
Bulgaria
ADARx Clinical Site
NOT_YET_RECRUITING
Sofia
Canada
ADARx Clinical Site
NOT_YET_RECRUITING
Edmonton
ADARx Clinical Site
NOT_YET_RECRUITING
Montreal
ADARx Clinical Site
NOT_YET_RECRUITING
Ottawa
China
ADARx Clinical Site
NOT_YET_RECRUITING
Beijing
ADARx Clinical Site
NOT_YET_RECRUITING
Harbin
ADARx Clinical Site
NOT_YET_RECRUITING
Zhengzhou
Croatia
ADARx Clinical Site
NOT_YET_RECRUITING
Split
ADARx Clinical Site
NOT_YET_RECRUITING
Zagreb
France
ADARx Clinical Site
NOT_YET_RECRUITING
Montpellier
ADARx Clinical Site
NOT_YET_RECRUITING
Nice
ADARx Clinical Site
NOT_YET_RECRUITING
Paris
ADARx Clinical Site
NOT_YET_RECRUITING
Tours
Germany
ADARx Clinical Site
NOT_YET_RECRUITING
Tübingen
Hong Kong Special Administrative Region
ADARx Clinical Site
NOT_YET_RECRUITING
Hong Kong
Hungary
ADARx Clinical Site
NOT_YET_RECRUITING
Budapest
Israel
ADARx Clinical Site
NOT_YET_RECRUITING
Ashkelon
ADARx Clinical Site
NOT_YET_RECRUITING
Tel Aviv
Poland
ADARx Clinical Site
NOT_YET_RECRUITING
Lodz
Spain
ADARx Clinical Site
NOT_YET_RECRUITING
Barcelona
ADARx Clinical Site
NOT_YET_RECRUITING
Madrid
Taiwan
ADARx Clinical Site
NOT_YET_RECRUITING
Taichung
United Kingdom
ADARx Clinical Site
NOT_YET_RECRUITING
Cambridge
ADARx Clinical Site
NOT_YET_RECRUITING
Cardiff
ADARx Clinical Site
NOT_YET_RECRUITING
London
ADARx Clinical Site
NOT_YET_RECRUITING
Southampton
Contact Information
Primary
Lupe Gallegos
info@adarx.com
877-232-7974
Time Frame
Start Date: 2026-04-02
Estimated Completion Date: 2030-06-30
Participants
Target number of participants: 90
Treatments
Experimental: ADX-324 Dose Level 1
Experimental: ADX-324 Dose Level 2
Related Therapeutic Areas
Sponsors
Leads: ADARx Pharmaceuticals, Inc.